Comment on Gyldenkerne et al. Negative Trend in Peripheral Artery Disease in Incident Type 2 Diabetes in Germany

We read with great interest the article by Gyldenkerne et al. (1), which was published in the January 2025 issue of Diabetes Care. We commend the authors for their insightful research on time trends in peripheral artery disease (PAD) among patients with incident type 2 diabetes (T2D). Their retrospective study, conducted in Denmark, highlights a significant decrease in the 5-year cumulative incidence of PAD (adjusted hazard ratio [aHR] 0.55 [95% CI 0.52–0.57]) between 1996–2000 and 2011–2015. T2D and PAD represent growing global health concerns, with important implications for cardiovascular and limb-related morbidity and mortality, quality of life, and health care resource use and costs (2). Diabetes is a recognized risk factor for PAD, and the occurrence of PAD in individuals with T2D serves to further increase the risk of long-term complications (2,3). The important study by Gyldenkerne et al. contributes valuable insights into the positive effects of improved diabetes management over time in the transition to the technology age.

Bekijk het originele bericht

Wellicht vindt u dit ook interessant

Meld u aan voor de maandelijkse nieuwsbrief

Patiëntvoorbeelden m.b.t. vergoeding

Voeg je koptekst hier toe

Vergoeding diabetesmiddelen

Apothekersinstructies:

Er zijn 2 soorten terugbetalingsregelingen:
* TBR: patiënt declareert online of per post of de apotheker declareert namens de patiënt online
** HEVO-Consult: patiënt betaalt kosten eerst zelf en stuurt declaratie naar HEVO-Consult